TOLERO PHARMACEUTICALS Trademark

Trademark Overview


On Wednesday, March 22, 2017, a trademark application was filed for TOLERO PHARMACEUTICALS with the United States Patent and Trademark Office. The USPTO has given the TOLERO PHARMACEUTICALS trademark a serial number of 79212382. The federal status of this trademark filing is REGISTERED as of Tuesday, July 3, 2018. This trademark is owned by Sumitomo Dainippon Pharma Co., Ltd.. The TOLERO PHARMACEUTICALS trademark is filed in the Pharmaceutical Products and Medical & Beauty Services & Agricultural Services categories with the following description:

Pharmaceutical preparations, namely, anti-inflammatories; pharmaceutical preparations for the prevention and treatment of disorders and diseases of the central nervous system, namely, diseases of the brain, movement, ocular motility and spinal cord diseases, encephalitis, epilepsy, Alzheimer's, cerebral palsy and Parkinson's disease and central nervous systems infections; pharmaceutical preparations for the prevention and treatment of disorders and diseases of the peripheral nervous system, namely, amyotrophic lateral sclerosis, numbness, lightheadedness, dysuria and dyshidrosis; pharmaceutical preparations for the prevention and treatment of disorders and diseases of the respiratory system; pharmaceutical preparations for the prevention and treatment of disorders and diseases of the urogenital system, namely, urological diseases, infertility, sexually transmitted diseases and inflammatory pelvic diseases; pharmaceutical preparations for the prevention and treatment of disorders and di...

Providing medical information
tolero pharmaceuticals

General Information


Serial Number79212382
Word MarkTOLERO PHARMACEUTICALS
Filing DateWednesday, March 22, 2017
Status700 - REGISTERED
Status DateTuesday, July 3, 2018
Registration Number5505386
Registration DateTuesday, July 3, 2018
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 17, 2018

Trademark Statements


Goods and ServicesPharmaceutical preparations, namely, anti-inflammatories; pharmaceutical preparations for the prevention and treatment of disorders and diseases of the central nervous system, namely, diseases of the brain, movement, ocular motility and spinal cord diseases, encephalitis, epilepsy, Alzheimer's, cerebral palsy and Parkinson's disease and central nervous systems infections; pharmaceutical preparations for the prevention and treatment of disorders and diseases of the peripheral nervous system, namely, amyotrophic lateral sclerosis, numbness, lightheadedness, dysuria and dyshidrosis; pharmaceutical preparations for the prevention and treatment of disorders and diseases of the respiratory system; pharmaceutical preparations for the prevention and treatment of disorders and diseases of the urogenital system, namely, urological diseases, infertility, sexually transmitted diseases and inflammatory pelvic diseases; pharmaceutical preparations for the prevention and treatment of disorders and diseases of the cardiovascular system; pharmaceutical preparations for the prevention and treatment of disorders and diseases of the endocrine system, namely, growth and thyroid disorders; pharmaceutical preparations for the prevention and treatment of disorders and diseases of the metabolic system, namely, diabetes, hypoglycemia, gout, osteoarthritis, muscular dystrophy, anemia, bulimia nervosa, anorexia, obesity and hypothyroidism; pharmaceutical preparations for the prevention and treatment of disorders and diseases of the renal system; pharmaceutical preparations for the prevention and treatment of disorders and diseases of the gastroenterological system; pharmaceutical preparations for the prevention and treatment of disorders and diseases of the ophthalmologic system; pharmaceutical preparations for the prevention and treatment of disorders and diseases of the dermatologic system, namely, dermatitis, eczema, psoriasis, skin pigmentation diseases and sexually transmitted diseases; pharmaceutical preparations for the prevention and treatment of hematologic and oncologic disorders and diseases; pharmaceutical preparations for the prevention and treatment of psychiatric disorders and diseases, namely, anxiety disorders, mood disorders, schizophrenia, cognitive and bipolar disorders, epilepsy, Parkinson's disease, Alzheimer's disease, cerebral palsy, multiple sclerosis and seizures; pharmaceutical preparations for the prevention and treatment of allergic disorders and diseases and disorders and diseases of the immune system, namely, autoimmune diseases and immunologic deficiency syndromes; pharmaceutical preparations for the prevention and treatment of connective tissue and joints, namely, connective tissue diseases, bone diseases, spinal diseases, back pain, fractures and cartilage injuries; pharmaceutical preparations for the prevention and treatment of cancer; pharmaceutical preparations for use in chemotherapy
Goods and ServicesProviding medical information
Disclaimer with Predetermined Text"PHARMACEUTICALS"

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, July 19, 2017
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateWednesday, July 19, 2017
Primary Code044
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameSumitomo Dainippon Pharma Co., Ltd.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressOsaka 541-0045
JP

Party NameSumitomo Dainippon Pharma Co., Ltd.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressOsaka 541-0045
JP

Party NameSumitomo Dainippon Pharma Co., Ltd.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressOsaka 541-0045
JP

Trademark Events


Event DateEvent Description
Monday, July 3, 2023COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Friday, October 26, 2018FINAL DECISION TRANSACTION PROCESSED BY IB
Thursday, October 4, 2018FINAL DISPOSITION NOTICE SENT TO IB
Thursday, October 4, 2018FINAL DISPOSITION PROCESSED
Wednesday, October 3, 2018FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Tuesday, July 3, 2018REGISTERED-PRINCIPAL REGISTER
Tuesday, April 17, 2018OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, April 17, 2018PUBLISHED FOR OPPOSITION
Friday, April 13, 2018NOTIFICATION PROCESSED BY IB
Wednesday, March 28, 2018NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Wednesday, March 28, 2018NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, March 28, 2018NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Thursday, March 15, 2018APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, March 14, 2018TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, March 13, 2018CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, March 13, 2018TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, December 22, 2017NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, December 22, 2017NON-FINAL ACTION E-MAILED
Friday, December 22, 2017NON-FINAL ACTION WRITTEN
Tuesday, December 19, 2017TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, December 19, 2017CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, December 15, 2017ASSIGNED TO LIE
Thursday, December 7, 2017TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, November 8, 2017ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, November 8, 2017TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Saturday, August 12, 2017REFUSAL PROCESSED BY IB
Thursday, July 27, 2017NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Thursday, July 27, 2017REFUSAL PROCESSED BY MPU
Tuesday, July 25, 2017APPLICATION FILING RECEIPT MAILED
Friday, July 21, 2017NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Thursday, July 20, 2017NON-FINAL ACTION WRITTEN
Wednesday, July 19, 2017ASSIGNED TO EXAMINER
Wednesday, July 19, 2017NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, July 14, 2017LIMITATION FROM ORIGINAL APPLICATION ENTERED
Thursday, July 13, 2017SN ASSIGNED FOR SECT 66A APPL FROM IB